Abstract
While the BNT162b2 (Pfizer-BioNTech) vaccine is known to protect against acute SARS-CoV-2 infection, its role in preventing Long COVID—clinically termed Post-Acute Sequelae of SARS-CoV-2 (PASC)—in pediatric populations remains less understood. This study evaluated the effectiveness of BNT162b2 against Long COVID across three cohorts: adolescents during the Delta phase, and both children and adolescents during the Omicron phase. Using causal mediation analysis on data from 20 health systems in the RECOVER PCORnet program, we found that the vaccine significantly reduces the risk of Long COVID. However, this protection is primarily mediated by the prevention of the initial infection rather than a reduction in PASC risk following a breakthrough infection.
Introduction
As the COVID-19 pandemic progressed, the long-term health impacts on children and adolescents became a significant public health concern. While vaccines were rapidly deployed, their effectiveness in mitigating Long COVID in younger populations was initially unclear. A major challenge in studying this is "selection bias" (specifically collider bias); comparing breakthrough infections in vaccinated individuals to infections in unvaccinated individuals can be misleading if the vaccine fundamentally alters the likelihood of infection itself.
This study sought to disentangle the vaccine's impact into two components: the indirect effect (protection gained by preventing infection entirely) and the direct effect (protection gained by altering the disease progression after an infection occurs).
Methods
Researchers conducted a real-world vaccine effectiveness study using electronic health record (EHR) data from the RECOVER PCORnet program, involving over 380,000 participants across three distinct cohorts:
- Adolescents (12–20 years) during the Delta phase (n=112,590)
- Children (5–11 years) during the Omicron phase (n=188,894)
- Adolescents (12–20 years) during the Omicron phase (n=84,735)
Causal Mediation Analysis
To separate the mechanisms of protection, the team employed causal mediation analysis. This framework allowed the decomposition of the "Total Effect" of the vaccine into the indirect effect (via infection prevention) and the direct effect (mitigation of PASC post-infection). To ensure the groups were comparable, propensity score weighting was used to balance variables such as age, sex, race, pre-existing conditions, and healthcare utilization patterns.
Key Results
Overall Vaccine Effectiveness (VE)
The study found substantial protection against Long COVID, though effectiveness varied by variant and age group:
- Adolescents (Delta): 95.4% effectiveness (95% CI: 90.9% to 97.7%)
- Adolescents (Omicron): 75.1% effectiveness (95% CI: 50.4% to 87.5%)
- Children (Omicron): 60.2% effectiveness (95% CI: 40.3% to 73.5%)
The "Infection Prevention" Engine
The mediation analysis revealed a critical insight: the vaccine’s protection against Long COVID is almost entirely indirect.
- Indirect Effects: Highly significant across all cohorts (Relative Risk ~0.04 for Delta adolescents; ~0.21–0.31 for Omicron cohorts). This indicates that the vaccine's primary value in preventing Long COVID lies in its ability to stop the initial infection.
- Direct Effects: Statistically non-significant in all three cohorts (estimates ranging from 0.91 to 1.24). This suggests that if a vaccinated child experiences a breakthrough infection, their risk of developing Long COVID is statistically similar to that of an unvaccinated child who becomes infected.
Discussion and Implications
The findings underscore that BNT162b2 is a powerful tool for reducing the burden of Long COVID in the pediatric population. However, the mechanism of this protection is specific: it acts as a shield against infection rather than a modifier of post-infection sequelae.
Limitations
As an observational study using EHR data, there are inherent limitations. The rise of home testing during the Omicron wave likely led to undocumented infections, which could affect the mediation estimates. Furthermore, while propensity score weighting was rigorous, unmeasured confounders such as individual masking behaviors or social distancing practices could influence the results. The study also focused on the primary vaccine series and does not account for the potential impact of booster doses or long-term waning immunity.
Conclusion
Vaccination with BNT162b2 remains a critical strategy for preventing Long COVID in children and adolescents. Because the protection is primarily driven by preventing the initial infection, maintaining high vaccination coverage is essential to mitigating the long-term tail of the pandemic in younger populations. Future research should continue to monitor these trends as new variants emerge and clinical definitions of Long COVID are refined.
Summary updated